Novel Model to Accurately Predict the Response Generated by Immunotherapy in Lung Cancer
Release Date: 20-Nov-2020
Selecting the correct treatment regimen for non-small cell lung cancer is estimated to be quite important for the overall treatment efficiency. According to the researchers, biomarkers can effectively change during therapy leading to change in the treatment procedure. Therefore, researchers from Moffitt Cancer Center are now focused towards the development of a novel non-invasive method to analyze the mutations present in the tumor cells as well as biomarkers in order to determine the best course of treatment.
The novel study is focused towards using positron emission tomography/computerized tomography (PET/CT) radiomics in order to determine whether non-small cell lung cancer is sensitive to tyrosine kinase inhibitor treatment and to identify the patients who will receive benefit from any immune checkpoint inhibitor therapy. Since the development of immunotherapy for the treatment of the patients suffering from non-small cell lung cancer, there has been an increasing demand of selecting the choice of treatment that could dynamically improve the condition of the patients. Therefore, majority of the researchers are compelled towards identifying comprehensive biomarkers that can be used longitudinally to help guide therapy choice.
So, 18F-FDG-PET/CT-based deep learning model developed by the researchers is believed to be highly accurate in demonstrating EGFR mutation status in the patients. It is known that the overexpression of EGFR protein in the body leads to uncontrolled growth of the cancer cells. Using the model developed by the researchers, EGFR mutations were predicted accurately and eventually it led to several other advantages such as identification of the accurate therapy for the patient. It led to high progression-free survival in patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitor immunotherapy. It is estimated that such studies in the medical world would lead to overall development of the cancer therapeutics market.
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.